Yellow fever vaccine (live) : List of nationally authorised medicinal products - PSUSA/00003135/202212

Declaration of interests: Silvy da Rocha Dias

Human medicines European public assessment report (EPAR): Capecitabine Accord, capecitabine, Colonic Neoplasms;Breast Neoplasms;Colorectal Neoplasms;Stomach Neoplasms, Date of authorisation: 20/04/2012, Revision: 16, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Adalimumab conjugated with (4S)-4-[2-(2-bromoacetamido)acetamido]-5-{3-[(4-{(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-4a,6a-dimethyl-2-oxo-6b-[(phosphonooxy)acetyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8-yl}phenyl)methyl] anilino}-5-oxopentanoic acid; (ABBV-154), decision type: , therapeutic area: , PIP number: P/0454/2021

Herbal medicinal product: Rhodiolae roseae rhizoma et radix, Rhodiolae roseae rhizoma et radix, F: Assessment finalised

Human medicines European public assessment report (EPAR): Neoclarityn, desloratadine, Rhinitis, Allergic, Perennial;Urticaria;Rhinitis, Allergic, Seasonal, Date of authorisation: 15/01/2001, Revision: 46, Status: Authorised

Human medicines European public assessment report (EPAR): Aerius, desloratadine, Rhinitis, Allergic, Perennial;Urticaria;Rhinitis, Allergic, Seasonal, Date of authorisation: 15/01/2001, Revision: 50, Status: Authorised

Herbal medicinal product: Origani majoranae herba, Origani majoranae herba, F: Assessment finalised

Human medicines European public assessment report (EPAR): Azomyr, desloratadine, Rhinitis, Allergic, Perennial;Urticaria;Rhinitis, Allergic, Seasonal, Date of authorisation: 15/01/2001, Revision: 52, Status: Authorised

Minutes of the COMP meeting 13-15 June 2023